Jim Allison, Sharon Belvin, Cancer discussed on On Point with Tom Ashbrook | Podcasts

Automatic TRANSCRIPT

You just knows it's a cell that's got stuff in on it. That shouldn't be there. And so and the beauty of that is well, two things. One is. You had a chance because you weren't targeting the cancer work against any kind of cancer. And so you know, that was that was, you know, sort of inherent in the model. And the other thing was since the primate starts by tumor cell death, you can give even conventional therapies like radiation and chemotherapy. Some of the benefits of of the immune response. For example, one of one, big lettuce. When you've got T-cells, you've got some for the rest of your life. And if the tumor happens to come back, the sales already, they're ready to go. Well, I wanna talk more about sort of the the the positives and potential drawbacks of immunotherapy in treating cancer, but later in the hour. But let me ask you, Jim Allison, do you remember the first patient that you worked with where you where you actually tried to see if it would make a difference in their lives and their treatment? They're actually to the first I met was woman. I can username because she's gonna be permission woman named Sharon belvin. It's it's, it's it's quite a to me touching story. I mean, I choked up every time I talk about it. I think about it, but she was twenty two years old just gotten out of college, and it was scheduled to be married when she was diagnosed with metastatic melanoma, and she had tumors center, lungs, thirty, one I believe is the cat and and someone scannon than even one in her in her brain. And at the time, if your diagnosis was about night about two thousand four at the time, if you received that kind of diagnosis to median survival was about eleven months. And there had been no drug at it ever. You know improved that. In a cynical trial. So she was told that she was basically they tried a bunch of chemotherapy. And she, you know, nothing more act. And finally, they proved on one of the early trials of this drug. It be Luma ma'am. What it's called, unfortunately, but her tumors went away within a few months and I met her when she was visiting and you know we're getting checked up. I should say in her in colleges Dr l. check said, you know, we tumors gone. We can't find anything, and I just moved there just I just recently anyway, he called her and said, well, the guy who invented this. I mean, he was with her. Sorry. And he said, the guy who invented this is is here you wanna meet him anyway, suggested called me and said, come to the outpatients. Ain't gonna say, well, I don't know. I'm busy and I said, no, no, no, you gotta come down here and so I did. And she hugged me and everybody started crying I cried and that was the first time. It really kind of dawned on me what was what was going on and. I talked with her occasionally after that. But about three years later, three years later she sent me a Votto prefers baby and then took a couple of years after that of her second baby. And so now she's basically fourteen years out because it's the treatment just given one one round. And so she's has beautiful family now. Well, we are talking with Jim Allison. He was awarded the two thousand eighteen Nobel prize in physiology or medicine for his work in cancer immunotherapy. He shares that a word with tusker Honjo Kyoto University, and we're talking about where we are in terms of revolutionary treatments for cancer, their their benefits. You just heard a huge benefit from Jim story about the first trait bed patient treated with his his research, but also we'll talk about the potential drawbacks as well, but why they're so so much excitement around cancer and immunological treatments. We'll be right back. I'm magnet, Tucker. Birdie. This is on. Point..

Coming up next